Suppr超能文献

III期宫颈癌的预后:一项双向结果研究。

Prognosis of stage III cervical cancer: a two-way outcome study.

作者信息

Zhou Huihui, Li Qi, Xu Chunyan, Liang Hong, Wang Yanan, Duan Yani, Song Min, Wang Yaoxian, Jin Hong, Wang Tong

机构信息

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin 150081, China.

Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, Harbin 150081, China.

出版信息

Transl Cancer Res. 2020 Apr;9(4):2565-2575. doi: 10.21037/tcr.2020.02.70.

Abstract

BACKGROUND

Cervical cancer is the second most common female malignancy worldwide, and the prognosis of patients with the locally advanced stage is poor, with a high risk of recurrent. This study aimed to explore the effect factors that influence the overall survival (OS), progression-free survival (PFS), and quality of life in patients with stage III cervical cancer.

METHODS

A two-way follow-up method was utilized to collect information from patients with stage III cervical cancer. Survival analyses were performed by the Kaplan-Meier method and Cox regression model. Multiple linear regression was used to analyze the factors related to quality of life.

RESULTS

Four hundred and sixty subjects were enrolled in this study. The median follow-up time was 28 months (range, 1-51 months). The 3-year OS and PFS rates were 69.0% and 55.0%, respectively. Primiparous age above 30 years, age at diagnosis below 40 years, lymph node metastasis, non-squamous cell carcinoma, and larger tumors were risk factors of OS and PFS, while the protective factors were weight loss, good mental status, and standardized treatment. The quality of life was better in patients with the following characteristics: younger age at diagnosis, active review according to medical orders, and earlier return to society.

CONCLUSIONS

Primiparous age above 30 years was a poor prognostic factor for OS, PFS, and quality of life. The common factors relevant to prognosis were confirmed to be significant.

摘要

背景

宫颈癌是全球第二常见的女性恶性肿瘤,局部晚期患者的预后较差,复发风险高。本研究旨在探讨影响III期宫颈癌患者总生存期(OS)、无进展生存期(PFS)和生活质量的影响因素。

方法

采用双向随访方法收集III期宫颈癌患者的信息。采用Kaplan-Meier法和Cox回归模型进行生存分析。采用多元线性回归分析与生活质量相关的因素。

结果

本研究共纳入460名受试者。中位随访时间为28个月(范围1-51个月)。3年总生存期和无进展生存期分别为69.0%和55.0%。初产年龄大于30岁、诊断时年龄小于40岁、淋巴结转移、非鳞状细胞癌和肿瘤较大是总生存期和无进展生存期的危险因素,而保护因素是体重减轻、精神状态良好和规范治疗。具有以下特征的患者生活质量较好:诊断时年龄较小、按医嘱积极复查、较早重返社会。

结论

初产年龄大于30岁是总生存期、无进展生存期和生活质量的不良预后因素。与预后相关的常见因素被证实具有显著性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7595/8798898/06b386cd36da/tcr-09-04-2565-f1.jpg

相似文献

1
Prognosis of stage III cervical cancer: a two-way outcome study.
Transl Cancer Res. 2020 Apr;9(4):2565-2575. doi: 10.21037/tcr.2020.02.70.
3
Significant effects of lymph and blood vascular invasion on the prognosis of early-stage cervical squamous cell carcinoma.
J Obstet Gynaecol Res. 2010 Oct;36(5):1015-22. doi: 10.1111/j.1447-0756.2010.01271.x. Epub 2010 Sep 16.
5
[Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):145-152. doi: 10.3760/cma.j.cn.441530-20201016-00561.
6
Cervical Cancer in Young Women: Do They Have a Worse Prognosis? A Retrospective Cohort Analysis in a Population of Mexico.
Oncologist. 2020 Sep;25(9):e1363-e1371. doi: 10.1634/theoncologist.2019-0902. Epub 2020 May 28.
7
Cervical Cancer in Women Aged 35 Years and Younger.
Clin Ther. 2016 Mar;38(3):459-66. doi: 10.1016/j.clinthera.2016.01.024. Epub 2016 Feb 18.
9
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
J Natl Cancer Inst. 1996 Oct 2;88(19):1361-8. doi: 10.1093/jnci/88.19.1361.
10
Overexpression of Ubiquilin4 is associated with poor prognosis in patients with cervical cancer.
World J Clin Cases. 2022 Mar 26;10(9):2783-2791. doi: 10.12998/wjcc.v10.i9.2783.

本文引用的文献

1
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. doi: 10.6004/jnccn.2019.0001.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Curr Oncol Rep. 2018 Apr 2;20(5):40. doi: 10.1007/s11912-018-0680-3.
5
Cervical Cancer Literacy in Women of Reproductive Age and Its Related Factors.
J Cancer Educ. 2019 Feb;34(1):82-89. doi: 10.1007/s13187-017-1270-z.
8
Quality of life of breast and cervical cancer survivors.
BMC Womens Health. 2017 Apr 12;17(1):30. doi: 10.1186/s12905-017-0387-x.
10
Real world evidence: An Indian perspective.
Perspect Clin Res. 2016 Oct-Dec;7(4):156-160. doi: 10.4103/2229-3485.192030.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验